New study shows small­er bio­phar­ma com­pa­nies strug­gle more than larg­er ones with clin­i­cal tri­al trans­paren­cy

As clin­i­cal tri­al trans­paren­cy and the shar­ing of pos­i­tive and neg­a­tive tri­al re­sults slow­ly be­come the norm rather than the ex­cep­tion, a new study pub­lished in the BMJ re­vealed strug­gles from small­er com­pa­nies to keep up with their larg­er ri­vals when it comes to trans­paren­cy.

Ab­b­Vie, Am­gen, Bay­er, Mer­ck KGaA/EMD Serono, No­var­tis, Roche and Take­da all tied for the top spot as the most trans­par­ent bio­phar­ma com­pa­nies, the study found.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.